Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma) secured overwhelming shareholder support at its 26 May 2026 annual general meeting, with all 13 resolutions passing by at least 99.42 % of votes cast. Turnout reached 254.94 million shares, representing 78.21 % of the company’s 325.98 million issued shares.

Key ordinary resolutions

• 2025 Annual Report, final accounts and the 2026 budget were approved, each drawing 99.81 % votes in favour. • Profit distribution, director remuneration for 2026 and the Board’s and Supervisory Board’s 2025 work reports were similarly endorsed. • Ernst & Young was re-appointed external auditor for 2026 at a fee cap of RMB 2.85 million (pre-tax).

Board renewal

Using cumulative voting, shareholders re-elected the entire slate of directors: – Executive Directors: Dr. Liu Yanjun, Ms. Wang Zheng and Ms. Li Cui – Non-executive Directors: Ms. Lin Chia-ling, Mr. Diao Juanhuan and Mr. Li Chen – Independent Non-executive Directors: Mr. Cai Zhongxi, Dr. Zeng Fanyi, Dr. Ju Dianwen and Mr. Zhang Senquan

Corporate governance overhaul

A special resolution (99.81 % support) amended the Articles of Association and eliminated the Board of Supervisors, replacing it with an employee representative director. Mr. Sun Yuhua, the company’s deputy general manager responsible for manufacturing, EHS and IT, was elected to that role.

Board leadership and committees

Immediately after the AGM, the new Board appointed: • Dr. Liu Yanjun as Chairman for a three-year term. • Committee chairs: Mr. Zhang Senquan (Audit), Mr. Cai Zhongxi (Nomination), Dr. Ju Dianwen (Remuneration) and Dr. Liu Yanjun (Strategy).

All changes take effect from 26 May 2026.